Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety, Tolerability, PK/PD, and Food Effect Study of OPC-131066 in Healthy Adult Males
jRCT2080224712Phase 1Terminated
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OPC-131066 (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of OPC-131066, Pharmacokinetics of OPC-131066 and 2 more. Started Jun 2019; status: terminated.
02
Drugs
OPC-131066
Beyond the preview
Go deeper on jRCT2080224712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224712.